Linda Avey is a founding general partner at Humain Ventures, an Austin, TX-based venture capital firm investing at the intersection of AI and the bioeconomy.
Linda has been at the forefront of the digital health movement. As the visionary founder of 23andMe in 2006, her mission to assemble a research repository of genetic and phenotypic data to study human disease achieved this goal. The company now houses the largest research database of recontactable participants. As co-founder of Precisely, Inc., she focused on methods to automate clinical protocols in order to improve outcomes and lower costs, in line with value-based care objectives.
Linda is a member of the Board of Fellows at Stanford Medical Center, and is an advisor to Colossal Biosciences. She was the founding independent board director at Rock Health, a leading digital health-focused fund, and served on the advisory board of Verily, Alphabet’s life science subsidiary.